P018 Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery

Baldan-Martin, M.(1);Azkargorta , M.(2);Iloro , I.(2);Ortega Moreno , L.(1);Aldars Garcia , L.(1);Soleto Fernández , I.(1);Ramirez , C.(1);Riestra , S.(3);Rivero , M.(4);Gutierrez , A.(5);Rodríguez-Lago , I.(6);Fernández-Salazar , L.(7);Ceballos , D.(8);Benítez , J.M.(9);Aguas , M.(10);Bastón-Rey , I.(11);Bermejo , F.(12);Casanova , M.J.(1);Llorente , R.(13);Ber , Y.(14);Royo , V.(15);Esteve , M.(16);Elortza , F.(2);Chaparro , M.(1);Gisbert , J.P.(1);

(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Madrid, Spain;(2)Proteomics Platform- CIC bioGUNE- BRTA Basque Research & Technology Alliance- CIBERehd- ProteoRed-ISCIII, Proteomics Platform, Derio, Spain;(3)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(4)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology Unit, Santander, Spain;(5)Hospital General Universitario de Alicante- ISABIAL and CIBERehd, Gastroenterology Unit, Alicante, Spain;(6)Hospital Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain;(7)Hospital Clínico Universitario de Valladolid, Gastroenterology Unit, Valladolid, Spain;(8)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology Unit, Las Palmas de Gran Canaria, Spain;(9)Hospital Universitario Reina Sofía and IMIBIC, Gastroenterology Unit, Córdoba, Spain;(10)Hospital Universitari i Politecnic La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain;(11)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(12)Hospital Universitario de Fuenlabrada and IDIPAZ, Gastroenterology Unit, Madrid, Spain;(13)Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain;(14)Hospital San Jorge, Gastroenterology Unit, Huesca, Spain;(15)Hospital Universitari Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain;(16)Hospital Universitari Mutua Terrasa and CIBERehd, Gastroenterology Unit, Terrasa, Spain;


Currently, endoscopy is the gold standard for the evaluation of disease activity and inflammation in clinical practice. However, it is an invasive procedure for the patient, costly and time-consuming. Therefore, there is an urgent need to identify non-invasive biomarkers with the potential clinical utility to diagnose inflammatory bowel disease (IBD) patients, improve the patient´s quality of life and increase efficiency in the Health Systems.


A label-free quantitative proteomics method was used to profile the urinary and serum proteomes of 100 patients with newly diagnosed IBD, before starting any treatment [50 patients with Crohn´s disease (CD) and 50 patients with ulcerative colitis (UC)] and 50 healthy controls (HC). The resulting peptides were separated by NanoLC (EVOSEP ONE) and coupled online by electrospray to Trapped Ion Mobility Spectrometry (TIMS) TOF Pro for tandem mass spectrometry analysis. Mass spectrometry data were processed and analyzed with MaxQuant and Perseus software. Proteins with p≤0.05 and ratio>1.5 in any sense, were considered as significantly dysregulated. Bioinformatic analysis of differentially expressed proteins was performed to characterize involved biological processes, molecular functions, cell locations and proteins pathways (PANTHER and STRING v11.5).


A total of 2,500 proteins were identified in the urine, and 468 proteins were identified in the serum with at least two different peptides at FDR<1%. Of the urine proteins, 110 were significantly changed in UC versus HC, 50 proteins were differentially expressed between CD and HC, and a total of 31 proteins were significantly changed in CD compared with UC patients (Figure 1). In serum samples, a total of 45 differentially expressed proteins were identified in the comparison between UC and HC groups, 32 proteins significantly expressed in CD versus HC, and 12 proteins in CD compared with UC (Figure 2). Finally, biological information analysis was performed according to these differential proteins. The molecular functions, biological processes, and pathways enriched mainly involved the neutrophil degranulation, complement and coagulation cascades and immune system responses (Figures 3 and 4).


Proteome profiling revealed significantly differences in newly diagnosed patients with CD or UC. Both serum and urine seem to be appropriate biological matrixes for this approach. Next steps of our research will be to understand the role of candidate proteins as well as to validate those with potential as biomarkers in independent cohort.